InvestorsHub Logo
icon url

FitzyP33

07/23/21 12:49 PM

#322436 RE: falconer66a #322430

We won't get results published until 2023, much less commercialization. Missling misses every deadline. That's just a fact. By "around" I mean relevant. Plenty of companies that trade at or below cash.

BTW - I do think Anavex will fail in one the indications. Note that I have no basis for that statement except when you swing a bunch of fastballs you're going to likely miss one.

If that happens it's definitely over.

I 100% hope I'm wrong and not just because of the money, but mostly because how transformative a working drug for Alz and the other CNS diseases would be.
icon url

frrol

07/23/21 1:02 PM

#322441 RE: falconer66a #322430

We don't "own it" and are not the only biotech pursuing S1 agonism as MOA.